AI-generated analysis. Always verify with the original filing.
Nyxoah reported fourth quarter 2025 net revenue of €5.6 million, representing 347% year-over-year growth, and full year 2025 net revenue of €10.0 million, up 122% year-over-year, driven by the first full quarter of U.S. commercialization following FDA approval in August 2025. The company had €48.0 million in cash, cash equivalents and financial assets at December 31, 2025, and expects U.S. net revenue to grow approximately 25% sequentially in Q1 and Q2 2026.
Event Type
Disclosure
Voluntary
Variant
6-K
Current Report on Form 6-K
| Metric | Value | Basis |
|---|---|---|
| Revenue | $5.60 | |
| Revenue | $10.00 | |
| Gross Profit | $3.60 | |
| Gross Margin | 64% | |
| Operating Loss | $18.60 | |
| Loss for the Period | $23.50 | |
| Basic Loss Per Share | $-0.59 |
U.S. Net Revenue
approximately 25% sequential growth